ENSG Stock Analysis: The Ensign | NASDAQ
Medical Care Facilities | NASDAQ, USA | Market Cap: 9.832m USD | 12M Return: 15.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 156M
EPS Trend: 99.3%
Qual. Beats: 0
Rev. Trend: 99.8%
Qual. Beats: -2
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
The Ensign Group, Inc. (ENSG) is a U.S. healthcare services company that provides skilled nursing, senior living, and rehabilitative care, operating through two segments. The Skilled Services segment delivers short- and long-term nursing care, specialty services such as on-site dialysis, ventilator care, and cardiac/pulmonary management, as well as standard room, board, and social services. The Standard Bearer segment acts as a real estate arm that leases post-acute care properties to affiliated and third-party healthcare operators, allowing Ensign to separate facility ownership from clinical operations. The company also runs senior living units and offers ancillary services including mobile diagnostics, in-facility pharmacy, respiratory therapy, and patient transportation.
Ensign operates facilities across 16 states, primarily in the western and southern U.S., and is headquartered in San Juan Capistrano, California. The split between operating companies and property-holding entities is a common structure in the post-acute and long-term care industry, where healthcare REITs and operators frequently segregate real estate assets from clinical operations to optimize capital efficiency and tax treatment. The skilled nursing and senior living sectors serve an aging population requiring chronic and post-hospitalization care, a demographic that has driven consistent demand for these services across the U.S.
- Skilled nursing occupancy and Medicare reimbursement updates
- Acquisition pace of distressed facilities drives footprint expansion
- Labor cost inflation pressures nursing home operating margins
| Net Income: 363.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 2.77 > 1.0 |
| NWC/Revenue: 8.95% < 20% (prev 6.36%; Δ 2.59% < -1%) |
| CFO/TA 0.11 > 3% & CFO 592.2m > Net Income 363.4m |
| Net Debt (3.75b) to EBITDA (594.4m): 6.31 < 3 |
| Current Ratio: 1.56 > 1.5 & < 3 |
| Outstanding Shares: last quarter (59.6m) vs 12m ago 1.82% < -2% |
| Gross Margin: 13.93% > 18% (prev 15.75%; Δ -1.82% > 0.5%) |
| Asset Turnover: 101.7% > 50% (prev 92.93%; Δ 8.77% > 0%) |
| Interest Coverage Ratio: 61.59 > 6 (EBIT TTM 485.5m / Interest Expense TTM 7.88m) |
| A: 0.08 (Total Current Assets 1.32b - Total Current Liabilities 848.0m) / Total Assets 5.61b |
| B: 0.33 (Retained Earnings 1.85b / Total Assets 5.61b) |
| C: 0.09 (EBIT TTM 485.5m / Avg Total Assets 5.19b) |
| D: 0.73 (Book Value of Equity 2.37b / Total Liabilities 3.24b) |
| Altman-Z'' = 3.02 = A |
| DSRI: 0.95 (Receivables 663.2m/584.0m, Revenue 5.27b/4.42b) |
| GMI: 1.13 (GM 15.75% / 13.93%) |
| AQI: 0.88 (AQ_t 0.08 / AQ_t-1 0.09) |
| SGI: 1.19 (Revenue 5.27b / 4.42b) |
| TATA: -0.04 (NI 363.4m - CFO 592.2m) / TA 5.61b) |
| Beneish M = -2.88 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 168.59 with a total of 322,697 shares traded. Over the past week, the price has changed by +0.22%, over one month by +11.22%, over three months by -15.26% and over the past year by +15.86%.
Current recommended Stop Loss: 161.70 (which is 4.1% or 1.3 ATR below the current price).
The Ensign has received a consensus analysts rating of 4.40. Therefore, it is recommended to buy ENSG.
- StrongBuy: 3
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 220.4 | 30.7% |
P/E Trailing = 27.3974
P/E Forward = 21.7865
P/S = 1.8642
P/B = 4.071
P/EG = 1.4534
Revenue TTM = 5.27b USD
EBIT TTM = 485.5m USD
EBITDA TTM = 594.4m USD
Long Term Debt = 136.5m USD (from longTermDebt, last quarter)
Short Term Debt = 120.8m USD (from shortTermDebt, last quarter)
Debt = 4.35b USD (from shortLongTermDebtTotal, last quarter) + Leases 2.10b
Net Debt = 3.75b USD (calculated: Debt 4.35b - CCE 595.2m)
Enterprise Value = 13.6b USD (9.83b + Debt 4.35b - CCE 595.2m)
Interest Coverage Ratio = 61.59 (Ebit TTM 485.5m / Interest Expense TTM 7.88m)
EV/FCF = 33.45x (Enterprise Value 13.6b / FCF TTM 406.1m)
FCF Yield = 2.99% (FCF TTM 406.1m / Enterprise Value 13.6b)
FCF Margin = 7.70% (FCF TTM 406.1m / Revenue TTM 5.27b)
Net Margin = 6.89% (Net Income TTM 363.4m / Revenue TTM 5.27b)
Gross Margin = 13.93% ((Revenue TTM 5.27b - Cost of Revenue TTM 4.54b) / Revenue TTM)
Gross Margin QoQ = 16.40% (prev 8.67%)
Tobins Q-Ratio = 2.42 (Enterprise Value 13.6b / Total Assets 5.61b)
Interest Expense / Debt = 0.18% (Interest Expense 7.88m / Debt 4.35b)
Taxrate = 23.86% (113.9m / 477.6m)
NOPAT = 369.7m (EBIT 485.5m * (1 - 23.86%))
Current Ratio = 1.56 (Total Current Assets 1.32b / Total Current Liabilities 848.0m)
Debt / Equity = 1.84 (Debt 4.35b / totalStockholderEquity, last quarter 2.37b)
Debt / EBITDA = 6.31 (Net Debt 3.75b / EBITDA 594.4m)
Debt / FCF = 9.24 (Net Debt 3.75b / FCF TTM 406.1m)
Total Stockholder Equity = 2.18b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.01% (Net Income 363.4m / Total Assets 5.61b)
RoE = 16.63% (Net Income TTM 363.4m / Total Stockholder Equity 2.18b)
RoCE = 20.92% (EBIT 485.5m / Capital Employed (Equity 2.18b + L.T.Debt 136.5m))
RoIC = 8.00% (NOPAT 369.7m / Invested Capital 4.62b)
WACC = 5.04% (E(9.83b)/V(14.2b) * Re(7.21%) + D(4.35b)/V(14.2b) * Rd(0.18%) * (1-Tc(0.24)))
Discount Rate = 7.21% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 85.63 | Cagr: 2.31%
[DCF] Terminal Value 77.97% ; FCFF base≈328.6m ; Y1≈376.7m ; Y5≈554.4m
[DCF] Fair Price = 78.52 (EV 8.34b - Net Debt 3.75b = Equity 4.59b / Shares 58.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.34 | EPS CAGR: 16.22% | SUE: 0.56 | # QB: 0
Revenue Correlation: 99.84 | Revenue CAGR: 16.81% | SUE: -0.85 | # QB: -2
EPS current Quarter (2026-06-30): EPS=1.85 | Chg30d=+0.11% | Revisions=+29% | Analysts=5
EPS next Quarter (2026-09-30): EPS=1.90 | Chg30d=+0.11% | Revisions=+38% | Analysts=5
EPS current Year (2026-12-31): EPS=7.56 | Chg30d=+0.00% | Revisions=+62% | GrowthEPS=+15.0% | GrowthRev=+15.5%
EPS next Year (2027-12-31): EPS=8.33 | Chg30d=+0.00% | Revisions=+62% | GrowthEPS=+10.2% | GrowthRev=+10.1%
[Analyst] Revisions Ratio: +68% (up=17, down=2)